Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea

Obstructive Sleep Apnea Clinical Trial

— ATLAST  

Official title:

The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01146782
• Other study ID #: 10753
• Status: Completed
• Phase: N/A
• First received: June 15, 2010
• Last updated: May 28, 2014
• Start date: June 2010
• Est. completion date: March 2012

Study information

• Verified date: May 2014
• Source: ApniCure, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This is a prospective study of the Attune Sleep Apnea System for the treatment of obstructive sleep apnea. The objective of the study is to demonstrate safety and effectiveness of the Attune Sleep Apnea System to support FDA marketing clearance of the device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 367
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject is between the ages of 18 and 80.

2. Diagnosis of OSA, based on ODI 10-60 (as assessed per home screening night).

3. Subject is fluent in English and understands the Study protocol and is willing and able to comply with Study requirements and sign the informed consent form.

4. BMI < 40.

5. Subject has a least one molar in each of the four quadrants of the mouth (right upper, right lower, left upper, and left lower).

6. Subject has proper mouthpiece fit, as assessed by home screening night (See section 8.3).

Exclusion Criteria:

1. OSA treatment within two weeks prior to Medical/Dental screening visit.

2. Poor nasal patency as evidenced by Peak Nasal Inspiratory Flow (PNIF) less than 75 l/min (assessed at baseline medical visit). In addition, any ongoing process or condition that limits nasal breathing or indications thereof, including: obligate mouth-breathing, persistent blockage of one or both nostrils resulting in the inability to sleep with the mouth closed, chronic nasal congestion, chronic allergic rhinitis, and intermittent allergic rhinitis that does not respond to non-sedating/non-stimulating medical therapy.

3. Oral cavity infection or any other oral or dental condition or problem that would limit subject use of the Attune Sleep Apnea System (e.g. dentures, loose tooth/teeth, temporomandibular joint (TMJ) conditions, or any oral or dental condition that the Investigator believes could be exacerbated by the Attune Sleep Apnea System.

4. Prior use of the Attune Sleep Apnea System.

5. History of any OSA surgical treatment including uvulopalatopharyngoplasty surgery (UPPP), maxillomandibular advancement surgery (MMA), radio frequency (RF) ablation treatment, palatal stent devices, etc.

6. Current use or use within the previous 2 weeks of medications or other agents that may affect sleep or PSG, including:

1. Hypnotics, anxiolytics, anticonvulsants, sedating antihistamines, stimulants, sedating antidepressants or other medications likely to affect neurocognitive function and/or alertness. Patients on stable selective serotonin reuptake inhibitor (SSRI) therapy for > 3 months and who are expected to remain on therapy for the Study duration, may continue SSRI treatment.

2. Consumption of > 500mg caffeine per day (e.g. > 8 cola-type beverages, > 5 cups of coffee).

3. Any known illicit drug use or abuse within the past year, or failure to pass drug urine screen test, or alcohol breathalyzer test with result over 0.05% BAL.

4. Smokers who smoke during the night (interference with PSG).

7. Any concomitant diagnosed or suspected sleep or chronic neurological disorders, other than OSA, including insomnia, and central sleep apnea.

8. Currently working nights, rotating night shifts, planned travel across four or more time zones required during Study period, or within two weeks prior to Study enrollment, or sleep schedule not compatible with sleep lab practices.

9. Potential sleep apnea complications that, in the opinion of the investigator, may affect the health or safety of the participant, including: low blood oxygen, recent near-miss or prior automobile accident due to sleepiness, reported history of severe cardiovascular disease (including NYHA class III or IV heart failure, CAD with angina or MI/stroke in past 6 months, uncontrolled hypertension or hypotension, cardiac arrhythmias), reported respiratory disorders, or use of medication or other treatment which may pose additional risk to the subject or confound the results of the Study.

10. Female subjects who are pregnant or intend to become pregnant during the study period.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Apnea
• Obstructive Sleep Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Device:
• Attune Sleep Apnea System
Console and mouthpiece sleep apnea system

Locations

Country	Name	City	State
United States	Sleep Disorders Center of Georgia (SDCG)	Atlanta	Georgia
United States	Peninsula Sleep Center	Burlingame	California
United States	SleepMed	Columbia	South Carolina
United States	Sleep Medicine Associates of Texas (SMAT)	Dallas	Texas
United States	SRI	Menlo Park	California
United States	REM Medical	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
ApniCure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of >50% and Treated AHI<20	Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and >30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of >50% and treated AHI<20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.	first treatment night	No
Secondary	Adverse Event Rate	Further categorized as serious and non-serious, device-related and non-device-related, unanticipated and anticipated, and based on level of severity. Adverse events will be evaluated during the trial at the following visits during 28-day take-home period: 7-day, 14-day, 21-day, 28-day follow-up, and any unscheduled visits.	4 weeks	Yes
Secondary	Last Treatment Night Response (AHI Reduction)	Comparing AHI at the last treatment night to the control/baseline night is reported as the percent change in AHI. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and >30/hr = severe OSA. Negative numbers represent a decrease/improvement in AHI, whereas positive numbers represent an increase/no improvement in AHI.	At completion of 28 day home use.	No
Secondary	Percent Reduction in Oxygen Desaturation Index (ODI)	Comparing first treatment night to control/baseline night reported as percent change. Negative numbers represent a reduction/improvement in ODI, whereas positive numbers represent increases/no improvement in ODI.	First treatment night	No